Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

Bayard L. Powell, MD
Published: Friday, Jan 09, 2015

Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at Wake Forest University Baptist Medical Center, discusses using the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).

The results of the recent phase I study look promising. The combination has been effective, with 54% of patients showing a response and no increased toxicity occurring from the addition of CPI-613. The combination was particularly beneficial for patients over 60 and patients with poor risk cytogenetics, says Powell.

Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at Wake Forest University Baptist Medical Center, discusses using the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).

The results of the recent phase I study look promising. The combination has been effective, with 54% of patients showing a response and no increased toxicity occurring from the addition of CPI-613. The combination was particularly beneficial for patients over 60 and patients with poor risk cytogenetics, says Powell.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x